3.4.21.37: leukocyte elastase
This is an abbreviated version!
For detailed information about leukocyte elastase, go to the full flat file.
Word Map on EC 3.4.21.37
-
3.4.21.37
-
pulmonary
-
cathepsin
-
airway
-
pancreatic
-
lavage
-
myeloperoxidase
-
hne
-
emphysema
-
fibrosis
-
cystic
-
bronchoalveolar
-
granule
-
elastin
-
sputum
-
bronchial
-
thrombin
-
chymotrypsin
-
coagulation
-
1-antitrypsin
-
neutropenia
-
interleukin-8
-
1-proteinase
-
degranulation
-
c-reactive
-
cardiopulmonary
-
elastolytic
-
antiprotease
-
serpins
-
mucus
-
slpi
-
alpha1-antitrypsin
-
azurophilic
-
aa
-
neutrophil-derived
-
elastases
-
2-macroglobulin
-
bronchiectasis
-
fmlp
-
elastase-induced
-
netosis
-
antineutrophil
-
proteinase-3
-
thrombin-antithrombin
-
ulinastatin
-
crevicular
-
neutrophil-mediated
-
ne-induced
-
beta-thromboglobulin
-
drug development
-
wegener
-
2-antiplasmin
-
diagnostics
-
medicine
- 3.4.21.37
- pulmonary
- cathepsin
- airway
- pancreatic
-
lavage
- myeloperoxidase
- hne
- emphysema
- fibrosis
-
cystic
-
bronchoalveolar
- granule
- elastin
- sputum
- bronchial
- thrombin
- chymotrypsin
- coagulation
-
1-antitrypsin
- neutropenia
- interleukin-8
-
1-proteinase
-
degranulation
-
c-reactive
-
cardiopulmonary
-
elastolytic
-
antiprotease
- serpins
- mucus
- slpi
- alpha1-antitrypsin
-
azurophilic
- aa
-
neutrophil-derived
- elastases
-
2-macroglobulin
- bronchiectasis
- fmlp
-
elastase-induced
-
netosis
-
antineutrophil
- proteinase-3
-
thrombin-antithrombin
- ulinastatin
-
crevicular
-
neutrophil-mediated
-
ne-induced
-
beta-thromboglobulin
- drug development
-
wegener
-
2-antiplasmin
- diagnostics
- medicine
Reaction
Hydrolysis of proteins, including elastin. Preferential cleavage Val-/- > Ala-/- =
Synonyms
bone marrow serine protease, EC 3.4.21.11, EC 3.4.4.7, ELA2, Elane, elastase, elaszym, granulocyte elastase, H2A specific protease, H2Asp, HLE, HNE, leukocyte elastase, lysosomal elastase, N-elastase, NE, neutrophil elastase, neutrophil-elastase, neutrophil-released elastase, PMN elastase, PMN-elastase, PMNE, polymorphonuclear leukocyte elastase, polymorphonuclear neutrophil elastase, serine elastase
ECTree
Advanced search results
Application
Application on EC 3.4.21.37 - leukocyte elastase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
drug development
medicine
-
the enzyme might be a useful indicator of the degree of surgical trauma in surgical procedures, in which occurs a massive release of PMN-elastase
diagnostics
-
measurement of neutrophile elastase in the crevicular fluid can help to distinguish healthy from inflamed periimplant and periodontal tissue
diagnostics
-
Plasma and urine leukocyte elastase-alpha1 protease inhibitor complex as a marker of of neutrophil degranulation and of early and long-term kidney graft function, evaluation, overview
-
neutrophil elastase may play be a target for the development of treatments for laminitis
drug development
-
suppression of the enzyme reduces the risk of preterm delivery and improved neonatal outcomes and is therefore a target for inhibitor development
-
the synthetic inhibitor 2,3-dihydro-6-[3-(2-hydroxymethyl)-phenyl-2-propenyl]5-benzofuranol may provide a new and useful therapeutic for the treatment of diseases characterized by polymorphonuclear elastase involvement
medicine
-
imbalance between elastase and its endogenous inhibitors may result in several pathophysiological states such as chronic obstructive pulmonary disease, asthma, emphysema, cystic fibrosis and chronic inflammatory diseases. An orally active leukocyte elastase can be useful for the treatment of these diseases. SSR69071 is a selective, orally active, and potent inhibitor of leukocyte elastase with good penetration in respiratory tissues
medicine
-
the enzyme has been implicated in the promotion or exacerbation of a number of diseases including pancreatitis acute respiratory distress syndrome, rheumatoid arthritis, atherosclerosis, pulmonary emphysema and cystic fibrosis. During the last decade, an intense effort has been directed towards the development of inhibitors to supplement the body elastase inhibitory capacity and thereby shift the proteinase/antiproteinase imbalance in pathogenic conditions. Several of these inhibitors have been produced by recombinant technology and formulations have been developed for aerosol and/or intravenous administration. The review focuses on low molecular-weight, synthetic inhibitors. A very small percentage of compounds possess all the necessary properties, including lack of toxicity, for progression into the clinic. ICI 200,880 has many of the desired characteristics of a drug to treat the diseases associated with human neutrophil elastase: chemical stability, in vitro and in vivo activity, a long duration of action and adequate metabolic stability. Currently ICI 200,880 is the only low molecular-weight inhibitor for neutrophil elastase known to be undergoing clinical trials, and may be the compound which finally demonstrates, the clinical utility of a synthetic neutrophil elastase inhibitor
medicine
-
peptidyl trifluoromethyl ketone inhibitors can achieve high levels of oral activity and bioavailibility, and therefore they may prove useful as therapeutic agents in the treatment of diseases in which elastase is implicated
medicine
-
the tosylalanine ester of 3-hydroxy-5-phenylpyrrole is localized on reagent strips and used diagnostically to test urine for the presence of human leukocyte elastase as an indication of urinary tract infection
medicine
-
neutrophil elastase is a mediator of atherosclerotic plaque development and a therapeutic target in atherosclerosis
medicine
-
neutrophil elastase is a target fot therapies in the treatment of cystic fibrosis
medicine
-
neutrophil elastase is involved in the development of anti-Thy1.1 nephritis
medicine
-
neutrophil elastase is needed for neutrophil emigration into lungs in ventilator-induced lung injury, neutrophil elastase is required for neutrophil egression from the vascular into the alveolar space, and interfering with this process leads to neutrophil-related endothelial cell injury
medicine
-
neutrophil elastase may contribute to neuronal death in hippocampal CA1 following forebrain ischemia
medicine
-
neutrophil elastase plays an important role in the progression of acute lung injury
medicine
-
It is feasible to administer neutrophil elastase inhibitor Sivelestat as a preventive measure against lung dysfunction after cardiopulmonary bypass
medicine
-
neutrophil elastase inhibitor sivelestat improves liver injury and prevents the increase of tissue malondialdehyde, MDA. Liver ischemia-reperfusion injury is one of the most serious complications of hepatic surgery
medicine
-
targeting neutrophil elastase represents a useful approach for preventing liver ischemia/reperfusion injury and hence expanding the organ donor pool and improving the overall success of liver transplantation
medicine
-
the enzyme inhibitor sivelestat sodium hydrate may attenuate neutrophil elastase or proinflammatory cytokines, and improve pulmonary dysfunction in patients undergoing a cardiopulmonary bypass and aortic valve replacement
medicine
neutrophil elastase is a major target for the development of compounds that inhibit the progression of long-term lung function decline in chronic obstructive pulmonary disease patients
medicine
-
enzyme activity is associated with predicted severity of acute pancreatitis and acute pancreatitis-associated respiratory failure